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ABSTRACT 
Two fungal cyclooligomer depsipeptide synthetases (CODSs), BbBEAS (352 kDa) and BbBSLS 
(348 kDa) from Beauveria bassiana ATCC 7159, were reconstituted in Saccharomyces 
cerevisiae BJ5464-NpgA, leading to the production of the corresponding anticancer natural 
products, beauvericins and bassianolide, respectively. The titers of beauvericins (33.82±1.41 
mg/l) and bassianolide (21.74±0.08 mg/l) in the engineered S. cerevisiae BJ5464-NpgA strains 
were comparable to those in the native producer B. bassiana. Feeding D-hydroxyisovaleric acid 
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(D-Hiv) and the corresponding L-amino acid precursors improved the production of beauvericins 
and bassianolide. However, the high price of D-Hiv limits its application in large-scale 
production of these cyclooligomer depsipeptides. Alternatively, we engineered another enzyme, 
ketoisovalerate reductase (KIVR) from B. bassiana, into S. cerevisiae BJ5464-NpgA for 
enhanced in situ synthesis of this expensive substrate. Co-expression of BbBEAS and KIVR in 
the yeast led to significant improvement of the production of beauvericins. The total titer of 
beauvericin and its congeners (beauvericins A, B and C) was increased to 61.73±2.96 mg/l and 
reached 2.6-fold of that in the native producer B. bassiana ATCC 7159. Supplement of L-Val at 
10 mM improved the supply of ketoisovalerate, the substrate of KIVR, which consequently 
further increased the total titer of beauvericins to 105.76±2.12 mg/l. Using this yeast system, we 
functionally characterized an unknown CODS from Fusarium venenatum NRRL 26139 as a 
beauvericin synthetase, which was named as FvBEAS. Our work thus provides a useful approach 
for functional reconstitution and engineering of fungal CODSs for efficient production of this 
family of anticancer molecules.  
Keywords: 
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Beauvericins 
Bassianolide 
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1. Introduction 
Nonribosomal peptides represent an important family of natural products, including 
antimicrobials, anticancer agents, immunosuppressants, siderophores, herbicides, antifungals, 
insecticides, and anthelminthics. They are biosynthesized by giant modular enzymes called 
nonribosomal peptide synthetases (NRPSs) (Fischbach and Walsh, 2006; Koglin and Walsh, 
2009). The assembly of the peptides is well programmed and controlled by the dedicated 
enzymes. Cyclooligomer depsipeptides (CODs) are a particular group of nonribosomal peptides 
often found in fungi as mycotoxins, such as beauvercins (1 and 3-5, Fig. 1), bassianolide (2, Fig. 
1) and enniatins. 1 is produced by a number of fungal strains such as Fusarium species, 
Beauveria bassiana, Paecilomyces fumoso-roseus (renamed Isaria fumosorosea), and P. tenuipes 
(renamed I. tenuipes) (Gupta et al., 1995; Molnar et al., 2010; Moretti et al., 2007; Nilanonta et 
al., 2002). It is a cyclic trimer of a dipeptidol monomer synthesized from 
N-methyl-L-phenylalanine and D-hydroxyisovaleric acid (D-Hiv). Its congeners, beauvericins 
A-C (3-5), were also observed as minor products in many producing strains. 2 was isolated from 
B. bassiana (Xu et al., 2008), Lecanicillium sp. (Molnar et al., 2010), and the wood-decaying 
Xylaria sp. BCC1067 (Jirakkakul et al., 2008). It is an octadepsipeptide that is assembled as the 
cyclic tetrameric ester of the dipeptidol monomer D-Hiv-N-Methyl-L-leucine. Fungal CODs have 
displayed a wide variety of bioactivities, including antibiotic, insecticidal, anthelminthic, 
herbicidal, antiretroviral, cytotoxic, anti-haptotactic, anti-cholesterol, and chemosensitizer 
activities, as well as repression of amyloid plaque formation in Alzheimer’s disease (Suessmuth 
et al., 2011). In addition, recent studies have shown that some fungal CODs are novel anticancer 
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agents (Ivanova et al., 2006; Lee et al., 2008). 1 has displayed potent anticancer activity against 
various cell lines by increasing cytoplasmic Ca2+ concentration, triggering ATP depletion, and 
activating calcium-sensitive cell apoptosis (Chen et al., 2006; Jow et al., 2004; Lin et al., 2005). 
Recently, we have found that 1 can also inhibit migration of the metastatic prostate cancer 
(PC-3M) and breast cancer (MDA-MB-231) cells, and has antiangiogenic activity in HUVEC-2 
cells at sublethal concentrations (Zhan et al., 2007). Inhibition of angiogenesis is an effective 
cancer chemotherapy strategy, and thus 1 may be a useful anticancer agent that restrains new 
tumor formation or increases successful containment of solid tumors. 2 was also shown to have 
moderate cytotoxic activity against different cancer cell lines (Jirakkakul et al., 2008). Therefore, 
these fungal natural products represent promising anticancer drug leads. 
Fungal CODs are assembled by COD synthetases (CODSs), a subclass of Type B NRPSs 
which use their modules iteratively for the biosynthesis of several copies of identical or nearly 
identical peptide/peptidol monomer units that remain covalently bound on the enzyme. The 
monomer units of CODs undergo recursive head-to-tail condensation, or oligomerization, 
followed by macrocyclization (Du and Lou, 2010). Typically, the monomers are formed from 
one unit of 2-hydroxycarboxylic acid and one molecule of amino acid. Two building blocks of 1 
are D-Hiv and L-phenylalanine (L-Phe), while 2 is biosynthesized from D-Hiv and L-leucine 
(L-Leu). We have previously used a precursor-directed biosynthesis approach to generate a series 
of new beauvericin analogs 6-11 (Fig. 1) by feeding 2-hydroxycarboxylic acids and amino acids 
into the fermentation broth of B. bassiana. The fluorine-containing products showed increased 
cytotoxicity while maintaining comparable antihaptotactic activity (Xu et al., 2007). These 
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results suggested that the dedicated CODS has relaxed substrate specificity and may represent an 
interesting target for engineered biosynthesis of new molecules. 
Both the biosynthetic gene clusters of 1 and 2 have recently been characterized from B. 
bassiana ATCC 7159 (Xu et al., 2009a; Xu et al., 2008). Analysis of the gene clusters revealed 
that the beauvericin synthetase (BbBEAS) and the bassianolide synthetase (BbBSLS) have the 
same domain organization of C1-A1-T1-C2-A2-MT-T2a-T2b-C3 (Fig. 2). In addition to the CODS 
gene, a kivr gene is found in the beauvericin biosynthetic gene cluster, which is proposed to be 
involved in the biosynthesis of D-Hiv (Xu et al., 2008). The detailed mechanism of these CODSs 
is not fully understood and requires more studies to demonstrate.  
Heterologous expression of CODSs in strains that are easier to manipulate genetically than 
the native fungal producers will facilitate enzymatic characterization of CODSs and their 
engineered variants, enable efficient production of these anticancer agents, and promote 
combinatorial biosynthesis of novel CODs. BbBEAS has been functionally expressed in 
Escherichia coli, but the best beauvericin titer was achieved at only 8 mg/l in E. coli when D-Hiv 
and L-Phe was supplemented (Xu et al., 2008). This represents less than 40% of the titer of the 
native producer B. bassiana, suggesting that E. coli is not an efficient host for the expression and 
functional reconstitution of the giant CODS. On the other hand, Saccharomyces cerevisiae is a 
fungus and may represent a better system for engineering of fungal CODSs. S. cerevisiae 
BJ5464-NpgA is an engineered yeast strain containing a chromosomal copy of the 
4'-phosphopantetheinyl transferase (PPTase) gene npgA from Aspergillus nidulans (Mootza et al., 
2002). PPTases catalyze the 4-phosphopantetheinylation of serine residues within T domains 
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using coenzyme A as the 4-phosphopantetheine donor to activate NRPSs (Mootza et al., 2002; 
Müller et al., 2012). Thus, it is essential to have a PPTase such as NpgA for functional expression 
of NRPSs in the yeast. S. cerevisiae BJ5464-NpgA has been used for functional reconstitution of 
giant enzymes such as the lovastatin nonaketide synthase, a highly reducing iterative polyketide 
synthase (PKS) (Ma et al., 2009). In the present study, we successfully engineered BbBEAS and 
BbBSLS into S. cerevisiae BJ5464-NpgA to reconstitute the production of 1-5. Supplement of 
the direct biosynthetic precursors (D-Hiv and L-Phe/L-Leu) improved the production of these 
CODs in the yeast. Furthermore, engineering of KIVR into the strain further enhanced the 
production of beauvericins, and improved supply of the substrate of KIVR by feeding L-Val led 
to an unprecedented high titer of beauvericins. Using this expression system, we also 
characterized a new beauvericin synthetase, named FvBEAS, from Fusarium venenatum NRRL 
26139. 
2. Materials and methods  
2.1. Strains, plasmids, and culture conditions
B. bassiana ATCC 7159 was obtained from the American Type Culture Collection (ATCC), 
maintained on potato dextrose agar (PDA), and fermented in potato dextrose broth (PDB) for the 
production of 1 and 2. Fermentation of B. bassiana ATCC 7159 was carried out in 250-ml flasks 
containing 100 ml of PDB on a rotary shaker at 250 rpm and 30°C for 4 days. F. venenatum 
NRRL 26139 was obtained from the Agricultural Research Service Culture Collection (NRRL), 
and fermented in DPY medium (20 g/l dextrin, 10 g/l multipeptone, 5 g/l yeast extract, 5 g/l 
monopotassium phosphate, 0.5 g/l magnesium sulfate) at 30°C for 6-8 days to produce 1. E. coli 
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XL1-Blue (Agilent) was used for routine cloning and pJET1.2 (Fermentas) was used as the 
cloning vector. E. coli cells were grown in Luria-Bertani (LB) medium. When necessary, 50 
g/ml of ampicillin was added. S. cerevisiae BJ5464-NpgA (MAT ura3-52 his3-200 leu2- 1 
trp1 pep4::HIS3 prb1 1.6R can1 GAL) was obtained from Dr. Nancy Da Silva at the University 
of California, Irvine. The plasmids pXW55 and pXW06 were gifts from Dr. Yi Tang at the 
University of California, Los Angeles. S. cerevisiae BJ5464-NpgA was maintained on YPD 
(yeast extract/peptone/dextrose) agar plates. The plasmid pXW55 carries the 
ampicillin-resistance gene and URA3 as the selection markers and was used as an E. coli/S. 
cerevisiae shuttle vector to express BbBEAS, BbBSLS and FvBEAS. The plasmid pXW06 
carries the ampicillin-resistance gene and TRP1 as the selection markers and was used as an E. 
coli/S. cerevisiae shuttle vector to express KIVR.  
2.2. DNA manipulations 
Genomic DNAs were extracted from B. bassiana ATCC 7159 and F. venenatum NRRL 
26139 and used as the templates for gene amplification. Plasmids were isolated from E. coli 
using a GeneJET™ Plasmid Miniprep Kit (Fermentas). Gene ligations were performed with T4 
DNA ligase (New England Biolabs). 
2.3. PCR amplification and plasmid construction 
The total size of bbBeas is 9,570 bp (GenBank accession number EU886196), and bbBsls 
contains 9,441 bp (GenBank accession number FJ439897). The gene fragments bbBeas-a (7.3 
kb), bbBeas-b (2.3 kb), bbBsls-a (6.9 kb), bbBsls-b (2.6 kb), and bbkivr (1,389 bp, GenBank 
accession number EU886196) were amplified by PCR from the genome of B. bassiana ATCC 
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7159 with Phusion® High-Fidelity DNA Polymerase (New England Biolabs) using specific 
primers (Table 1). The fvBeas gene contains 9,390 bp and was deposited in GenBank under 
accession number JX975482. Similarly, two fragments of this gene, fvBeas-a (3.4 kb) and 
fvBeas-b (6.0 kb), were amplified from the F. venenatum NRRL 26139 genome. These gene 
fragments were ligated into the cloning vector pJET1.2 to yield seven plasmids including 
pJCZ47, pJCZ48, pJCZ49, pJCZ50, pDY47, pDY55 and pDY56 (Table 2). These plasmids were 
confirmed by digestion checks and gene sequencing.  
The bbBeas-b insert was excised from pJCZ48 with NheI and PmlI and ligated into pXW55 
between the same sites to generate pDY35, and then bbBeas-a was excised from pJCZ49 with 
NheI and inserted into pDY35 at the same site to generate pDY37 (Table 2 and Fig. S1). The 
bbBsls-b insert was excised from pJCZ47 with NdeI and PmlI and ligated into pXW55 between 
the same sites to generate pDY36. The bbBsls-a insert was excised from pJCZ50 with NdeI and 
ligated into pDY36 at the same site to yield pDY42 (Table 2). The fvBeas-b insert was excised 
from pDY56 with NdeI and PmlI and ligated into pXW55 between the same sites to generate 
pDY57, and then the fvBeas-a insert was excised from pDY55 with NdeI and ligated into pDY57 
at the same site to generate pDY59 (Table 2). The bbkivr insert was excised from pDY47 with 
NdeI and PmeI and ligated into pXW06 between the same sites to generate pDY48 (Table 2 and 
Fig. S2). 
2.4. Transformation and fermentation of S. cerevisiae BJ5464-NpgA 
Transformation of plasmid pDY37, pDY42 or pDY59 and co-transformation of pDY37 and 
pDY48 into S. cerevisiae BJ5464-NpgA competent cells, as well as the selection of correct 
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transformants were conducted as previously described (Gietz and Schiestl, 2007). The 
engineered S. cerevisiae strain carrying pDY37, pDY42 or pDY59 was fermented in a SC-Ura 
dropout medium (6.7 g/l yeast nitrogen base; 20 g/l glucose; 0.77 g/l -Ura DO supplement) at 
30°C with shaking at 250 rpm until the OD600 reached 0.6, and then equal volume of YP medium 
(10 g/l yeast extract; 20 g/l peptone) with or without extra substrates was added. The cultures 
were maintained under the same conditions for an additional 72 h to produce the CODs. S. 
cerevisiae BJ5464-NpgA/pDY37+pDY48 was fermented in a SC-Ura-Trp dropout medium (6.7 
g/l yeast nitrogen base; 20 g/l glucose; 0.72 g/l -Trp/-Ura DO supplement) at 30°C with shaking 
at 250 rpm until the OD600 reached 0.6, and then equal volume of YP medium with or without 
extra substrates was added. The fermentation broths were cultured under the same conditions for 
an additional 72 h to produce beauvericins. S. cerevisiae BJ5464-NpgA/pDY37+pDY48 was 
also grown at 20°C to compare the titer with that at 30°C. 
2.5. Extraction, isolation, and analysis of metabolites in the wild type fungal strains and 
engineered S. cerevisiae strains 
The culture of B. bassiana ATCC 7159 was filtered through Whatman No. 1 filter paper. The 
filtrate was extracted three times with the same volume of ethyl acetate. The mycelium cake 
from 100 ml of fermentation broth was extracted twice with 50 ml of methanol. The extracts 
were concentrated under reduced pressure and dissolved in 500 l of methanol for LC-MS 
analysis. Extraction of the culture of F. venenatum NRRL 26139 was performed using the same 
method.  
To purify 1 and 2 for establishing the standard curves, fermentation of B. bassiana ATCC 
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7159 was carried out in a 2-l flask containing 500 ml of PDB on a rotary shaker at 250 rpm and 
30°C for 4 days. The fermentation broth was then extracted as described above. A small portion 
(10%) of the extract was separated on an Agilent 1200 HPLC using an Agilent Ecilpse 
XDB-C18 column (5 m, 4.6 mm × 150 mm column), washed with a gradient of methanol-water 
(80% to 100% over 20 min) at a flow rate of 1 ml/min. The peaks at 9.6 min and 12.6 min were 
collected to yield 1.7 mg of 1 and 1.2 mg of 2. These two samples were dissolved in 500 l of 
methanol, which was serially diluted to obtain different concentrations. For each concentration, 
100 l of these samples were injected into the HPLC to obtain the peak areas to establish 
standard curves for 1 and 2. Compounds 1 and 3-5 were purified using the same HPLC method 
from the fermentation broth of S. cerevisiae BJ5464-NpgA/pDY37 for structural characterization. 
Standard curves based on the linear relationship between the amounts and the peak areas were 
established for 3-5 for quantification of their production in different engineered strains. Similarly, 
2 was isolated from S. cerevisiae BJ5464-NpgA/pDY42 for structural characterization. NMR 
spectra were acquired on a JEOL instrument (300 MHz).    
To analyze the products in the engineered S. cerevisiae BJ5464-NpgA strains, 100 ml of 
fermentation broth was centrifuged at 2,737 ×g for 5 min to pellet the cells. The supernatant was 
extracted three times with the same volume of ethyl acetate, and the cells were extracted twice 
with 50 ml of methanol. The extracts were evaporated in vacuo to remove the solvents. The 
residues were then dissolved in 500 l of methanol and analyzed on an Agilent 6130 Single 
Quad LC-MS, eluted with a gradient of methanol-water (80% to 100% over 20 min) at a flow 
rate of 1 ml/min and detected at 210 nm. 
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2.6. Extraction and analysis of the production of D-Hiv in S. cerevisiae BJ5464-NpgA/pDY37 
and S. cerevisiae BJ5464-NpgA/pDY37+pDY48  
S. cerevisiae BJ5464-NpgA/pDY37 and S. cerevisiae BJ5464-NpgA/pDY37+pDY48 were 
grown and harvested as described above. For each strain, the concentrations of D-Hiv in the cells 
and supernatants were measured separately 24 and 48 h after the addition of YP medium. 
Experiments were conducted in triplicate. The cells were extracted by 50 ml of methanol twice 
and the supernatant was extracted by 100 ml of ethyl acetate for three times. The extracts were 
dried in vacuo and re-dissolved in 500 l of methanol for HPLC analysis. The samples were 
analyzed by HPLC at 210 nm, eluted with 15% methanol-water containing 0.1% formic acid for 
15 min. The retention time of D-Hiv is 11.9 min. A standard curve of D-Hiv (VWR) was 
established to quantify the concentration of this compound in the cells and supernatants.   
3. Results
3.1. Reconstitution of BbBEAS and BbBSLS in S. cerevisiae BJ5464-NpgA  
The expression plasmids pDY37 and pDY42, which carry bbBeas and bbBsls, respectively, 
were introduced into S. cerevisiae BJ5464-NpgA and the engineered strains were fermented to 
reconstitute the biosynthesis of 1 and 2, respectively. As shown in Fig. 3a, HPLC analysis of S. 
cerevisiae BJ5464-NpgA/pDY37 indicated that peak 1 at 9.6 min was produced as a major 
product. The retention time and UV spectrum of 1were the same as those for beauvericin 
produced by the original producing strain, B. bassiana ATCC 7159. ESI-MS (Fig. 3b) showed a 
series of quasimolecular ion peaks, including [M+H]+ at m/z 784.1, [M+NH4]+ at m/z 801.4, 
[M+Na]+ at m/z 806.3 and [M+K]+ at m/z 822.3, which is consistent with the molecular weight of 
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beauvericin (Fig. S3a). Three analogs 3-5 were also produced. ESI-MS analysis of these 
compounds (Fig. 3d-f) showed that their molecular weights were 797, 811 and 825, respectively, 
same as those of beauvericins A, B and C produced by the original host B. bassiana (Fig. S3c-e). 
We purified these four products from S. cerevisiae BJ5464-NpgA/pDY37 for structural analysis 
(Fig. S4). The NMR data of these compounds (Supplementary Materials, Fig. S5 and S6) are in 
agreement with those reported for beauvericin(Gupta et al., 1995; Zhan et al., 2007), beauvericin 
A (Gupta et al., 1995), beauvericin B (Gupta et al., 1995), and beauvericin C (Nilanonta et al., 
2002), which confirmed the successful reconstitution of beauvericins in the yeast. Similarly, peak 
2 at 12.6 min in trace (iii) of Fig. 3a was found to be a major product in S. cerevisiae 
BJ5464-NpgA/pDY42. ESI-MS analysis (Fig. 3c) revealed that it has the same molecular weight 
as bassianolide produced by B. bassiana (Fig. S3b). This compound was then purified from S. 
cerevisiae BJ5464-NpgA/pDY42 (Fig. S4) and subjected to NMR analysis. A comparison of the 
NMR data of 2 (Supplementary Materials) with the literature (Jirakkakul et al., 2008; Suzuki et 
al., 1977) confirmed that this compound is bassianolide. The titers of these fungal CODs were 
determined and are shown in Table 3. The titers of 1 and 2 were close to those in the native 
producer B. bassiana, which were 22.26±1.48 and 18.19±0.62 mg/l, respectively.  
3.2. Improvement of the production of fungal CODs in S. cerevisiae by supplement of the 
biosynthetic precursors 
D-Hiv and L-amino acid are essential substrates for the synthesis of 1-5 (Suessmuth et al., 
2011). It is apparent that S. cerevisiae can provide these biosynthetic precursors since we have 
been able to reconstitute the production of 1-5 in this yeast by only expressing the corresponding 
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CODSs. However, the supply of these precursors may not be sufficient to allow these 
heterologous CODSs to work at their full catalytic capacity. Thus, it is possible that supplement 
of the direct biosynthetic precursors will improve the titers of these compounds. To test the 
effects of addition of D-Hiv and L-Phe on the production of beauvericins, the fermentation broth 
of S. cerevisiae BJ5464-NpgA/pDY37 was fed with these two precursors at two different final 
concentrations, 0.8 and 2.0 mM. As shown in Table 3, at these two concentrations, the titer of 1 
was increased to 29.69±1.91 and 36.08±3.44 mg/l, respectively. In contrast, the production of 3-5 
was negatively influenced. While the titer of 3 was slightly decreased, the biosynthesis of 4 and 5 
was completely not detectable at 2 mM of D-Hiv and L-Phe. The overall titer of all these 
beauvericins was increased from 33.82±1.41 mg/l (without supplemented precursors) to 
38.54±0.64 mg/l (0.8 mM precursors) and 42.25±1.35 mg/l (2.0 mM precursors). Similarly, the 
fermentation broth of S. cerevisiae BJ5464-NpgA/pDY42 was fed with D-Hiv and L-Leu at 0.8 
and 2.0 mM, which led to the obvious increase in the production of 2 as shown in Table 3.       
3.3. Effects of co-expression of KIVR on beauvericin biosynthesis in S. cerevisiae 
Although supplement of D-Hiv and L-amino acids apparently increased the titers of 1-5 in the 
engineered S. cerevisiae strains, the high cost of D-Hiv may hamper its use in large-scale 
production of these anticancer compounds. Thus, an improved in situ synthesis of D-Hiv in the 
yeast represents an attractive approach for enhanced biosynthesis of fungal CODs. Fungi 
biosynthesize D-Hiv by reducing the appropriate free ketocarboxylic acids, derived from amino 
acid catabolic and anabolic pathways. The beauvericin biosynthetic gene cluster in B. bassiana 
was found to contain a kivr gene encoding a putative reductase with a GxGxxGxxxA 
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NAD(P)H-binding signature, which is highly similar to COG1893 ketopantoate reductases (Xu 
et al., 2009b). No similar gene was clustered with the bbBsls gene in the same strain. Thus, 
KIVR was proposed to supply D-Hiv for the biosynthesis of both 1 and 2. This was confirmed by 
disruption of kivr in the genome of B. bassiana, which abolished the production of both 1 and 2 
in the fungus. Chemical complementation of the mutant by supplementing the fermentation 
medium with D-Hiv restored the production of both CODs (Xu et al., 2009b). Thus, KIVR is the 
dedicated enzyme that synthesizes D-Hiv in B. bassiana for COD biosynthesis.  
We next examined whether co-expression of KIVR with CODSs in S. cerevisiae 
BJ5464-NpgA will increase the titers of these CODs. The kivr gene was cloned into pXW06, and 
the resulting plasmid pDY48 was co-expressed in S. cerevisiae BJ5464-NpgA with pDY37. The 
engineered strain, S. cerevisiae BJ5464-NpgA/pDY37+pDY48, thus contains a two-enzyme 
system composed of BbBEAS and KIVR. LC-MS analysis of the products revealed the 
production of 1 and its congeners 3-5. Compared to S. cerevisiae BJ5464-NpgA/pDY37, this 
double transformant produced the same compounds except that the ratio of the products was 
different (Fig. S7). While 1 was the major product in S. cerevisiae BJ5464-NpgA/pDY37, 3 was 
found to be the most abundant product in S. cerevisiae BJ5464-NpgA/pDY37+pDY48.  
The titers of 1 and 3-5 in S. cerevisiae BJ5464-NpgA/pDY37+pDY48 were measured. As 
shown in Table 4, although the titer of 1 was slightly lower than that in S. cerevisiae 
BJ5464-NpgA/pDY37 (Table 3), co-expression of KIVR and BbBEAS enhanced the production 
of 3-5 more than 3-fold. The total titer of beauvericins in S. cerevisiae 
BJ5464-NpgA/pDY37+pDY48 reached 61.73±2.96 mg/l, a 2-fold increase compared to that in S. 
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cerevisiae BJ5464-NpgA/pDY37. We also measured the production of D-Hiv in the yeast strains 
with and without KIVR. As shown in Table 5, D-Hiv was detected in both cells and supernatants 
and the production of D-Hiv in S. cerevisiae BJ5464-NpgA/pDY37+pDY48 was higher than in S. 
cerevisiae BJ5464-NpgA/pDY37, further confirming that the expression of KIVR has enhanced 
D-Hiv biosynthesis in the yeast.  
A previous study on the production of -(L--aminoadipyl)-L-cysteinyl-D-valine in S. 
cerevisiae reported that a 30-fold enhancement of the product titer was achieved by lowering the 
cultivation temperature from 30C to 20C (Siewers et al., 2009). To test the effects of 
fermentation temperatures on beauvericin biosynthesis, we also cultured S. cerevisiae 
BJ5464-NpgA/pDY37+pDY48 at 20C and measured the titer of beauvericins at 3 and 5 days. 
We found that the production of these compounds at 20C were approximately 50% of that at 
30C.    
3.4. Effects of supplement of L-amino acids on beauvericin biosynthesis in S. cerevisiae 
D-Hiv and D-2-hydroxy-3-methylvalerate (D-Hmv) are common biosynthetic precursors for 
COD biosynthesis. D-Hiv is used in the biosynthesis of 1 and D-Hmv is a precursor for the 
biosynthesis of 5, while the biosynthesis of 3 and 4 requires both substrates. D-Hiv and D-Hmv 
can be synthesized from the intermediates from both amino acid catabolic and anabolic pathways. 
One of the possible biosynthetic pathways using the -keto acids from amino acid catabolism 
was proposed in Fig. 4. L-Val is converted into -ketoisovalerate (Kiv) by a branched-chain 
amino acid transaminase, which was subsequently transformed into D-Hiv by KIVR. Similarly, 
D-Hmv can be synthesized from L-Ile catabolism. To examine whether supplement of L-amino 
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acids can improve beauvericin biosynthesis in the yeast, L-Val or L-Ile was fed to the 
fermentation broth of S. cerevisiae BJ5464-NpgA/pDY37+pDY48 at different concentrations. 
The growth of the yeast strain was not influenced by addition of these amino acids at the tested 
concentrations, as the final OD600 values were approximately 2.0 for all the cultures. It was found 
that supplement of L-Val significantly improved the production of 1 in S. cerevisiae. As shown in 
trace (i) of Fig. S8, the peak of 1 became predominant and the production of 4 and 5 was almost 
undetectable. Four different concentrations (3, 10, 30 and 100 mM) of L-Val were added into the 
fermentation broth of S. cerevisiae BJ5464-NpgA/pDY37+pDY48 and the titers of beauvericins 
were measured. As seen in Fig. 5a, the titer of 1 was increased to 47.49±0.55, 69.25±0.95, and 
74.06±0.28 mg/l, respectively, when 3, 10 and 30 mM L-Val was supplemented. However, when 
the concentration of L-Val was increased to 100 mM, the titer of 1 slightly dropped. The titer of 3 
was increased when 3 and 10 mM L-Val was supplied, while higher concentrations (30 and 100 
mM) led to a decrease in the production of 3. The titers of 4 and 5 were decreased at all four 
tested concentrations of L-Val. The overall titer of all beauvericins was increased to 93.14±1.82, 
105.76±2.13, 92.99±0.71 and 67.32±1.21 mg/l, respectively, at the four tested concentrations.  
Supplement of L-Ile had a different effect on the production of beauvericins. The ratio of the 
different beauvericins has changed. As shown in trace (ii) of Fig. S8, when 10 mM L-Ile was 
supplemented, 5 became the most abundant product, with 1 as a minor product. The titers of the 
products are shown in Fig. 5b. The titer of 1 was decreased to 11.51±0.36, 6.86±0.61, 2.24±0.17, 
and 0.64±0.18 mg/l, respectively, when L-Ile was supplemented at 1, 3, 10 and 30 mM. Similarly, 
the titer of 3 was also decreased. The titer of 4 was increased to 18.11±0.35 and 19.49±1.21 mg/l, 
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respectively, at 1 and 3 mM, but was decreased to 14.68±0.53 and 4.15±0.35 mg/l when 10 mM 
and 30 mM L-Ile was supplied. The titer of 5 was increased at the first three concentrations of 
L-Ile, but dropped when 30 mM of L-Ile was supplemented. The overall titer of total beauvericins 
was decreased to 57.92±1.19, 52.68±1.53, 38.77±1.41, and 12.37±1.70 mg/l at the four 
concentrations. 
3.5. Functional characterization of a new beauvericin synthetase from F. venenatum  
 To further examine whether the activity of CODSs from other fungi could also be 
reconstituted in the yeast using this expression system, a putative CODS gene, fvBeas, was 
amplified from the genome of F. venenatum NRRL 26139. This gene contains 9,390 bp and 
analysis of the deduced amino acid sequence indicated that it is a putative CODS with the same 
domain organization as BbBEAS and BbBSLS. BLAST analysis of the deduced protein revealed 
that FvBEAS shares 58% identity and 74% similarity with BbBEAS (GenBank accession 
number ACI30655), and 57% identity and 73% similarity with BbBSLS (GenBank accession 
number ACR78148). Using a similar approach for the cloning of bbBeas and bbBsls, this gene 
was ligated into pXW55 to yield the expression plasmid pDY59, which was subsequently 
expressed in S. cerevisiae BJ5464-NpgA. Both the wild type F. venenatum and S. cerevisiae 
BJ5464-NpgA/pDY59 were fermented for product analysis. As shown in trace (i) of Fig. S9, the 
major metabolite in F. venenatum NRRL 26139 was confirmed to be 1 by LC-MS analysis, 
suggesting that fvBeas encodes a beauvericin synthetase. This was confirmed by detection of 1 in 
S. cerevisiae BJ5464-NpgA/pDY59, as shown in trace (ii) of Fig. S9. Thus, FvBEAS was 
functionally reconstituted in S. cerevisiae BJ5464-NpgA and was identified as a beauvericin 
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synthetase.    
4. Discussion 
Fungal CODSs represent an important group of natrally occurring molecules, which have 
shown a variety of biolgoical activities. The compounds studied in this work, 1-5, were found to 
be promising anticancer molecules. In spite of formidable technical difficulties, heterologous 
production of secondary metabolites is increasingly feasible (Halo et al., 2008; Zirkle et al., 
2004). 1 has been previously produced in E. coli by expressing BbBEAS in E. coli (Xu et al., 
2008). However, the titer is low. When the engineered E. coli strain was fermented at 16°C, with 
supplement of 15 mM D-Hiv and L-Phe, the final titer of 1 only reached approximately 8 mg/l, 
which is far less than that in the native producer (Xu et al., 2008). Thus, a convenient, fast and 
low-cost biosynthetic way to produce these anticancer molecules is desireable. In this work, we 
expressed BbBEAS and BbBSLS in S. cerevisiae BJ5464-NpgA. S. cerevisiae BJ5464-NpgA is 
a genetically modified strain that contains a chromosomal copy of the PPTase NpgA that is 
necessary for activation of NRPSs. This strain has been previously used for heterologous 
expression of several giant modular enzymes such as LovB, a PKS involved in lovastatin 
biosynthesis (Ma et al., 2009). Unlike the native producer B. bassiana ATCC 7159, which 
produces 1 and 2 as the major products, expression of BbBEAS in S. cerevisiae BJ5464-NpgA 
led to the production of a series of beauvericins, including 1 and 3-5. Production of these 
different beauvericins indicated that S. cerevisiae can supply two different 2-hydroxycarboxylate 
precursors for beauvericin biosynthesis. This also revealed that BbBEAS, or more specifically 
the A1 domain of BbBEAS, has relatively relaxed substrate specificity. In addition to the natural 
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substrate D-Hiv, the A1 domain can select and load D-Hmv as an alternative substrate onto the 
CODS to yield 3-5. BbBEAS takes three units of D-Hiv and L-Phe as the biosynthetic precursors 
to synthesize 1. When one unit of D-Hmv is taken, 3 will be synthesized by BbBEAS. 
Incorporation of two units of D-Hmv led to the production of 4. When the three units of D-Hiv 
are completely replaced by D-Hmv, 5 will be produced. The production of 3-5 in relatively larger 
amounts is likely due to more abundant supply of D-Hmv in the yeast than B. bassiana. 
Reconstitution of BbBSLS further confirmed that fungal CODSs can be reconstituted in S. 
cerevisiae. Although expression of catalytic fragments of the enniatin synthetase has been done 
(Hornbogen et al., 2007), reconstitution of entire fungal CODSs in S. cerevisiae has not 
previously been achieved. This work thus represents the first example of functional 
reconstitution of fungal CODSs in S. cerevisiae. Unlike E. coli which requires exogenous supply 
of D-Hiv for the production of 1, S. cerevisiae can directly supply the biosynthetic precursors 
D-Hiv and D-Hmv for the production of CODs.  
Supplement of D-Hiv and L-Phe into the fermentation broth of S. cerevisiae 
BJ5464-NpgA/pDY37 led to an increase in the production of 1, while decreased the production 
of 3-5. This may be attributed to the increased supply of the direct precursors of 1. The 
supplemented D-Hiv, together with the synthesized D-Hiv by the host, might have dominated the 
binding site of BbBEAS. This makes it more difficult for D-Hmv to be incorporated into the 
products. Thus, the product type is dominated by the relative amount of the available substrates. 
The overall titer of total beauvericins was increased due to the addition of D-Hiv and L-Phe. The 
titer of 2 was also increased when D-Hiv and L-Leu were supplied, confirming that substrate 
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feeding is useful in improving the biosynthesis of CODs in S. cerevisiae, which also indicated 
that the supply of these precursors in the yeast is relatively insufficient for the catalytic capacity 
of the expressed enzymes.  
KIVR has been previously reported to supply D-Hiv for the biosynthesis of both 1 and 2 in B. 
bassiana ATCC 7159, as disruption of kivr in this fungus abolished the biosynthesis of these 
compounds (Xu et al., 2009b). Because the high cost of D-Hiv makes it an expensive material for 
large-scale production of these anticancer CODs, we further engineered KIVR from B. bassiana 
into S. cerevisiae BJ5464-NpgA. We found that expression of KIVR in S. cerevisiae 
BJ5464-NpgA increased the concentration of D-Hiv in the cells and fermentation broth. While 
measurements of the concentration of D-Hiv provide a snapshot of the dynamic synthesis process 
of this precurosr, the increased metabolic flux was reflected in the significantly increased titer of 
total beauvericins in S. cerevisiae BJ5464-NpgA/pDY37+pDY48. It was expected that the 
expression of KIVR will lead to better supply of D-Hiv and higher titer of 1. However, it is 
interesting that the titers of 3-5 were increased, while the production of 1 was slightly decreased. 
This result suggested that KIVR is not strictly substrate specific and can synthesize both D-Hiv 
and D-Hmv in the yeast. This is similar to a KIVR recently characterized from Fusarium 
proliferatum LF061, which takes 2-ketovalerate, pyruvate, 2-ketocapronate, 2-ketoglutarate and 
2-ketobutyrate in addition to Kiv, although the enzymatic activity towards these unnatural 
substrates was low (Zhang et al., 2012). In this work, we found that KIVR can efficiently 
synthesize D-Hmv, resulting in a significant increase in the formation of 3-5. This enzyme 
utilizes Kiv to synthesize D-Hiv, and reduces -keto--methylvalerate (Kmv) into D-Hmv (Fig. 
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4). Kiv is an important metabolite from both L-Val catabolic and anabolic pathways. In S. 
cerevisiae, a bidirectional reaction between L-Val and Kiv is catalyzed by the branched-chain 
amino-acid aminotransferases Bat1 and Bat2, which are present in the mitochondrial matrix and 
the cytosol, respectively (Kispal et al., 1996; Lilly et al., 2006). Similarly, Kmv can be obtained 
from both L-Ile catabolism and anabolism. The structural compositions, the decreased titer of 1 
and the increased titers of 3-5 suggested that much more D-Hmv was synthesized by the 
heterologous KIVR than D-Hiv in the yeast. This might be due to the different supply of Kmv 
and Kiv in the host or a substrate preference of KIVR to Kmv. In contrast, 1 was found to be the 
predominant product in B. bassiana, while 3-5 were only produced in small amounts. It is likely 
that the supply of Kiv, and consequently D-Hiv, was dominant in B. bassiana. This indicated that 
production of the substrates for KIVR in the native host and the yeast was different, which led to 
different production profiles of beauvericins in these strains.  
One of the major sources of 2-hydroxycarboxylate precursors is the catabolism of L-amino 
acids, as proposed in Fig. 4. Supplement of L-Val significantly increased the titer of beauvericins. 
More specifically, the ratio of the products has changed and 1 became the predominant 
metabolite in S. cerevisiae BJ5464-NpgA/pDY37+pDY48. Because the only 
2-hydroxycarboxylate precursor for 1 is D-Hiv, improved biosynthesis of D-Hiv from the 
supplemented L-Val directly facilitated the biosynthesis of 1. In contrast, the production of 3 and 
4 was limited by the supply of the second precursor D-Hmv. The presence of large amount of 
D-Hiv reduced or even abolished the production of 5, likely due to the substrate competition 
between D-Hiv and D-Hmv. Our work enabled the production of beauvericins at an 
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unprecedented high level of 105.76±2.12 mg/l in S. cerevisiae when 10 mM L-Val was 
supplemented. This titer is approximately 4-fold of that in the native producer, which was 
24.49±1.52 mg/l in the presence of the same concentration of L-Val. Thus, this work provides an 
efficient production process for these anticancer natural products. Higher concentrations 
decreased the production of beauvericins, likely due to the over occupation of the active site of 
BbBEAS by excess D-Hiv, which may lower the efficiency of this giant modular enzyme.  
Supplement of L-Ile was supposed to improve the supply of D-Hmv, which was confirmed by 
the predominant production of 5 (Fig. S8). However, it was unexpected the overall titer of 
beauvericins was decreased. Since the growth of the yeast cells was not affected, supplemented 
L-Ile might have interfered with the expression or function of BbBEAS in S. cerevisiae. Overall, 
our feeding experiments confirmed that supplement of L-Val is an effective approach to 
enhancing the in situ supply of D-Hiv and the production of beauvericins.  
Overexpression of the pathway-specific regulator has been previously shown to significantly 
improve the titer of cytochalasin E from 25 to 175 mg/l in Aspergillus clavatus NRRL 1 (Qiao et 
al., 2011), suggesting that this is a useful approach to enhancing natural product biosynthesis. 
Similarly, overexpression of the dedicated ABC transporter AvtAB improved avermectin 
production about two-fold in Streptomyces avermitilis (Qiu et al., 2011). Thus, further 
improvement of the titer of beauvericins may be achieved by overexpression of the related 
regulator and transporter in the beauvericin biosynthetic pathway. No transporter gene exists in 
the reported beauvericin biosynthetic gene cluster, while a gene orf1 encoding a putative 
Gal4-like transcriptional regulator with a Zn2Cys6 binuclear cluster DNA-binding domain was 
 23 
 
located in the flanking region of bbBeas on the genome of B. bassiana ATCC 7159 (Xu et al., 
2008). Although it is unclear whether this regulator is associated with beauvericin biosynthesis, 
this regulator represents a potential target for further improvement of beauvericins. Other KIVR 
analogues, such as the one recently identified in F. proliferatum LF061 that has broad substrate 
specificity, can also be engineered into the system to generate novel beauvericins (Zhang et al., 
2012). Additionally, further understanding of the catalytic properties of BbBEAS and KIVR will 
also provide useful information for future engineering of these enzymes for improved efficiency.  
5. Conclusions
In this work, we examined the heterologous reconsititution of fungal CODSs in S. cerevisiae 
and production of the corresponding anticancer CODs. The activities of two fungal CODSs, 
BbBEAS and BbBSLS from B. bassiana ATCC 7159, were reconstituted efficiently in S. 
cerevisiae BJ5464-NpgA. The titers of the anticancer natural products, beauvericins and 
bassianolide, are comparable to those in the native producer. Supplement of the biosynthetic 
precursors, D-Hiv and L-amino acids (L-Phe or L-Leu) can significantly increase the production 
of these CODs in the yeast. Alternatively, we co-expressed BbBEAS and KIVR in S. cerevisiae 
BJ5464-NpgA, leading to a nearly 100% increase in the total titer of beauvericins (from 33.82 to 
61.73 mg/l). Furthermore, we fed L-Val and L-Ile into the engineered strain S. cerevisiae 
BJ5464-NpgA/pDY37+pDY48 to test the effects of these amino acids on the production of 
beauvericins at different concentrations. The titer of beauvercins reached 105.76±2.12 mg/l when 
10 mM L-Val was supplemented. The best titer of 1 was achieved at 74.06±0.28 mg/l when 30 
mM L-Val was supplemented. With this efficient expression system, we also functionally 
 24 
 
characterized a CODS from F. venenatum NRRL 26139 as a new beauvericin synthetase, which 
was named as FvBEAS. This work provides a useful platform for functional reconstitution of 
fungal CODSs and efficient production of the corresponding natural products.   
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Figure captions 
Fig. 1. Naturally occurring and biosynthesized fungal CODs (1-11). Beauvericin (1), 
bassianolide (2), beauvericins A-C (3-5) are natural products. Beauvericins G1-G3 (6-8) and 
beauvericins H1-H3 (9-11) were produced by precursor-directed biosynthesis. 
Fig. 2. Domain organization of BbBEAS and BbBSLS. 
Fig. 3. LC-MS analysis of the production of 1-5 in B. bassiana ATCC 7159 and engineered S. 
cerevisiae strains. (a) HPLC traces of the extracts of B. bassiana ATCC 7159 (i), S. cerevisiae 
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BJ5464-NpgA/pDY37 (ii), and S. cerevisiae BJ5464-NpgA/pDY42 (iii). (b) ESI-MS spectrum of 
1. (c) ESI-MS spectrum of 2. (d) ESI-MS spectrum of 3. (e) ESI-MS spectrum of 4. (f) ESI-MS 
spectrum of 5. All experiments were performed in triplicate, and a representative result was 
shown.  
Fig. 4. Proposed biosynthesis of D-Hmv and D-Hiv by KIVR in S. cerevisiae. The substrates of 
KIVR can be recruited from both amino acid catabolic and anabolic pathways. This proposed 
biosynthetic pathway only shows the KIVR substrates from the catabolic pathways.  
Fig. 5. Effects of supplement of L-Val and L-Ile on the production of 1 and its congeners 3-5 in S. 
cerevisiae BJ5464-NpgA/pDY37+pDY48. (a) Titers of beauvericins in S. cerevisiae 
BJ5464-NpgA/pDY37+pDY48 when various concentrations of L-Val were supplemented. (b) 
Titers of beauvericins in S. cerevisiae BJ5464-NpgA/pDY37+pDY48 when various 
concentrations of L-Ile were supplemented. Data are presented as means ± SD (n = 3). 
Highlights 
 First reconstitution of two CODSs, BbBEAS and BbBSLS, was achieved in S. cerevisiae.
 Co-expression of KIVR and BbBEAS significantly enhanced beauvericin biosynthesis.
 Supplement of L-Val increased the yield of beauvericins to 105.76 mg/l. 
 A new beauvericin synthetase was functionally identified from F. venenatum.
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Table 1 
Primers used in this study. 
 
Primer Sequence Restriction site 
bbBeas-a-F        
bbBeas-a-R 
5'-aaGCTAGCatggagccgctcaaaaatgt-3' 
5'-tcggcgGCTAGCtgcacaag-3' 
NheI 
NheI 
bbBeas-b-F        
bbBeas-b-R 
5'-ttgtgcaGCTAGCcgccgag-3' 
5'-aaCACGTGcaaagccgagtttagactct-3' 
NheI 
PmlI 
bbBsls-a-F 
bbBsls-a-R 
5'-aaCATATGgagccacccaacaacgc-3' 
5'-ttgtgCATATGggatgcttg-3' 
NdeI 
NdeI 
bbBsls-b-F 
bbBsls-b-R 
5'-aagcatccCATATGcacaag-3' 
5'-aaCACGTGtaaagacgcattcaaagcct-3' 
NdeI 
PmlI 
bbkivr-F 
bbkivr-R 
5'-aaCATATGccatctccggagcatcc-3' 
5'-aaGTTTAAACttacaacagccttctcgcca-3' 
NdeI 
PmeI 
fvBeas-a-F 
fvBeas-a-R 
5'-aaCATATGgaatatcttactgctgt-3' 
5'-tctcacagCATATGgaatca-3' 
NdeI 
NdeI 
fvBeas-b-F 
fvBeas-b-R 
5'-tctgattcCATATGctgtga-3' 
5'-aaCACGTGcaaagaagagttgagaccct-3' 
NdeI 
PmlI 
 
 
Table 1
Table 2 
Plasmids constructed in this study. 
 
Plasmid     Description Plasmid Description 
pJCZ49 bbBeas-a in pJET1.2 pDY35 bbBeas-b in pXW55 
pJCZ48 bbBeas-b in pJET1.2 pDY37 bbBeas-a and bbBeas-b in pXW55 
pJCZ50 bbBsls-a in pJET1.2 pDY36 bbBsls-b in pXW55 
pJCZ47 bbBsls-b in pJET1.2 pDY42 bbBsls-a and bbBsls-b in pXW55 
pDY47 bbkivr in pJET1.2 pDY48 bbkivr in pXW06 
pDY55 fvBeas-a in pJET1.2 pDY57 fvBeas-b in pXW55 
pDY56 fvBeas-b in pJET1.2 pDY59 fvBeas-a and fvBeas-b in pXW55 
 
 
 
 
Table 2
Table 3 
Titers of 1-5 in engineered S. cerevisiae BJ5464-NpgA strains with or without supplemented 
biosynthetic precursors (D-Hiv and L-Phe for S. cerevisiae BJ5464-NpgA/pDY37; D-Hiv and L-
Leu for S. cerevisiae BJ5464-NpgA/pDY42). Data are presented as means ± SD (n = 3). 
 
 Titer (mg/l) 
Precursor concentration 0 mM 0.8 mM 2.0 mM 
pDY37 
1 21.89±0.77 29.69±1.91 36.08±3.44 
3 7.12±0.15 6.65±0.11 6.15±0.20 
4 3.41±0.25 1.68±0.46 ND* 
5 1.40±0.24 0.52±0.22 ND* 
Total beauvericins 33.82±1.41 38.54±0.64 42.23±1.35 
pDY42 2 21.74±0.08 23.90±2.22 26.74±2.75 
 
* ND: not detected. 
 
Table 3
 Table 4 
Titers of beauvercins in S. cerevisiae BJ5464-NpgA/pDY37+pDY48. Data are presented as 
means ± SD (n = 3). 
 
 
 
 
 
 
 
 
 
 
 
 Titers (mg/l) 
1 19.44±1.38 
3 21.62±1.31 
4 14.74±1.11 
5 5.93±0.23 
Total beauvericins 61.73±2.96 
Table 4
 Table 5  
Production of D-Hiv in S. cerevisiae BJ5464-NpgA/pDY37 and S. cerevisiae BJ5464-
NpgA/pDY37+pDY48. Data are presented as means ± SD (n = 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  pDY37 pDY37+pDY48 
24 h 
supernatant 5.15±0.08 mg/l 6.36±0.07 mg/l 
cells 2.99±0.07 mg/l 4.89±0.17 mg/l 
Total 8.12±0.15 mg/l 11.26±0.25 mg/l 
48 h 
supernatant 6.61±0.45 mg/l 8.71±1.04 mg/l 
cells 3.68±0.05 mg/l 6.63±0.09 mg/l 
Total 10.28±0.39 mg/l 15.34±1.14 mg/l 
Tables
